Skip to content

To Study the safety and effectiveness of Laser Treatment in Glaucoma patients

A prospective trial to evaluate the safety and efficacy of the STEAM (Scleral Translocation Elasto-Modulation) procedure for the treatment of glaucoma in Indian adults - STEAM-G

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008071
Enrollment
60
Registered
2017-03-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Unilateral Glaucoma in Sighted and Unsighted Patients

Interventions

Intervention1: LASER: STEAM delivery device operates as a continuous wave infra-red laser is scanned over a thermally stabilized sclera to create a precise (i.e., pre-programmed) subsurface annular sh

Sponsors

Aleyegn Technologies LLC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Male and female subjects are eligible for the study if they are 18 years old or older and have given informed consent • Have moderate to severe glaucoma (24 mm Hg to 45 mm Hg IOP) with or without visual field damage • Have primary open angle glaucoma, angle closure glaucoma, ocular hypertension, secondary glaucoma, previous intraocular surgery • Are able to follow up for one year • Able to provide written informed consent

Exclusion criteria

Exclusion criteria: • Patients younger than 18 years or older than 80 years • Patients not willing to participate in the study • Patients having Vernal Keratoconjunctivitis • Corneal Scar / corneal dystrophy / corneal degeneration • Inflammatory conditions • Patients with corneal hydrops • Patients with Diabetes, Thyroid Dysfunction, Collagen-Vascular Disorders, Auto-Immune Disorders; Hypertensives can be included provided there would be no change in the systemic treatment during the study period • Patients not able to come for follow up • Ultrasonic pachymetry • Eyes with any ocular surface infection • Endothelial cell count

Design outcomes

Primary

MeasureTime frame
Accommodative amplitude change from pre-Op on Binocular Auto-refractor (Grand Seiko 5500) Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.

Secondary

MeasureTime frame
Best spectacle-corrected Visual Acuity (BSCVA)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;ComplicationsTimepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;Defocus Curve (iTracey)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;Intraocular pressure (Goldmann applanation)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;Manifest refraction (Phoropter)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;Need for adjunctive surgeryTimepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;Uncorrected Visual Acuity (UCVA)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.;UNVA (Jaeger chart)Timepoint: Pre-Op (-30 days). Day of surgery (Day 0), Post-Op: Day 1, Week 1, Month 1, Month 3, Month 6, and Month 12.

Countries

India

Contacts

Public ContactDr Sirisha Senthil

LV Prasad Eye Institute

sirishasenthil@lvpei.org04030612121

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026